Delving into the Latest Updates on Zhejiang Fukang Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Congenital Disorders

Immune System Diseases

Bispecific antibody

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Hemic and Lymphatic Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

Bispecific antibody	1
Small molecule drug	1

Top 5 Target	Count

PDL1 x VEGF	1
PI3Kβ x PI3Kδ	1

主要研究目的 :评价CVL006单药在晚期实体瘤患者中的安全性和耐受性；观察CVL006单药在晚期实体瘤中的剂量限制性毒性（DLT），评估最大耐受剂量（MTD）及推荐的II期临床研究的使用剂量（RP2D）。次要研究目的：观察CVL006注射液单药在晚期实体瘤患者中的药代动力学（PK）特征；初步评价CVL006单药在晚期实体瘤患者中的有效性（包括客观缓解率[ORR]、肿瘤缓解持续时间[DoR]、疾病控制率[DCR]、最佳反应率[BOR]、无进展生存期[PFS]）。（根据RECIST1.1标准）；评价CVL006的免疫原性。

[Translation]

Main study objectives: To evaluate the safety and tolerability of CVL006 monotherapy in patients with advanced solid tumors; To observe the dose-limiting toxicity (DLT) of CVL006 monotherapy in advanced solid tumors, and to evaluate the maximum tolerated dose (MTD) and the recommended dose for Phase II clinical studies (RP2D). Secondary study objectives: To observe the pharmacokinetic (PK) characteristics of CVL006 injection monotherapy in patients with advanced solid tumors; To preliminarily evaluate the effectiveness of CVL006 monotherapy in patients with advanced solid tumors (including objective response rate [ORR], duration of tumor response [DoR], disease control rate [DCR], best response rate [BOR], progression-free survival [PFS]). (According to RECIST1.1 criteria); To evaluate the immunogenicity of CVL006.

Start Date-

Sponsor / Collaborator

Zhejiang Fukang Pharmaceutical Co., Ltd.

[+1]

CTR20240229

/ RecruitingPhase 2

CVL237 片治疗 PTEN 缺失的晚期实体瘤的单臂、开放、多中心、II 期临床研究

[Translation] A single-arm, open-label, multicenter, phase II clinical study of CVL237 tablets in the treatment of advanced solid tumors with PTEN deficiency

1、主要研究目的：评估 CVL237 片在 PTEN 缺失的晚期实体瘤患者中的初步有效性。 2、次要研究目的： (1) 评估 CVL237 在 PTEN 缺失的晚期实体瘤患者中的安全性； (2) 评估 CVL237 在 PTEN 缺失的晚期实体瘤患者中的药代动力学特征； (3) 初步探索生物标记物与抗肿瘤活性的关系。

[Translation]

1. Primary study objectives: To evaluate the preliminary efficacy of CVL237 tablets in patients with advanced solid tumors with PTEN deletion. 2. Secondary study objectives: (1) To evaluate the safety of CVL237 in patients with advanced solid tumors with PTEN deletion; (2) To evaluate the pharmacokinetic characteristics of CVL237 in patients with advanced solid tumors with PTEN deletion; (3) To preliminarily explore the relationship between biomarkers and anti-tumor activity.

Start Date25 Mar 2024

Sponsor / Collaborator

Zhejiang Fukang Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Zhejiang Fukang Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Zhejiang Fukang Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Zhejiang Fukang Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Zhejiang Fukang Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Approval

1

Phase 1 Clinical

Phase 2 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

KA-2237 ( PI3Kβ x PI3Kδ )	Breast Cancer More	Phase 2
CVL-006 ( PDL1 x VEGF )	Advanced Malignant Solid Neoplasm More	Phase 1
Neratinib maleate ( EGFR x HER2 x HER4 )	HER2 Positive Solid Tumors More	IND Approval